BNP Paribas Financial Markets’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

BNP Paribas Financial Markets’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-812,820	Closed	-$720K	–	4134
2022 Q4	$720K	Sell	812,820 -109,647	-12%	-$145K	﹤0.01%	2362
2022 Q3	$1.45M	Buy	922,467 +833,596	+938%	+$1.89M	﹤0.01%	2208
2022 Q2	$179K	Buy	88,871 +63,976	+257%	+$111K	﹤0.01%	3140
2022 Q1	$58K	Sell	24,895 -39,198	-61%	-$122K	﹤0.01%	3526
2021 Q4	$298K	Buy	64,093 +13,817	+27%	+$85.8K	﹤0.01%	3248
2021 Q3	$384K	Buy	50,276 +40,171	+398%	+$341K	﹤0.01%	2850
2021 Q2	$97.9K	Sell	10,105 -22,121	-69%	-$176K	﹤0.01%	3050
2021 Q1	$267K	Buy	32,226 +3,714	+13%	+$39.2K	﹤0.01%	2905
2020 Q4	$195K	Sell	28,512 -94,136	-77%	-$756K	﹤0.01%	2893
2020 Q3	$1.37M	Sell	122,648 -149,210	-55%	-$1.37M	﹤0.01%	1666
2020 Q2	$1.71M	Buy	271,858 +229,252	+538%	+$878K	﹤0.01%	1575
2020 Q1	$78.4K	Buy	42,606 +24,717	+138%	+$71.2K	﹤0.01%	3330
2019 Q4	$60.5K	Sell	17,889 -401	-2%	-$956	﹤0.01%	3535
2019 Q3	$39.1K	Buy	18,290 +3,836	+27%	+$8.94K	﹤0.01%	3616
2019 Q2	$38.6K	Sell	14,454 -9,964	-41%	-$35.9K	﹤0.01%	3590
2019 Q1	$116K	Buy	+24,418	New	+$64.1K	﹤0.01%	3038
2018 Q4	–	Sell	-3,343	Closed	-$14.7K	–	4471
2018 Q3	$14.7K	Buy	3,343 +500	+18%	+$2.77K	﹤0.01%	3563
2018 Q2	$20.5K	Buy	+2,843	New	+$19.3K	﹤0.01%	3485
2017 Q2	–	Sell	-240	Closed	-$948	–	4366
2017 Q1	$948	Sell	240 -1,185	-83%	-$5.94K	﹤0.01%	3709
2016 Q4	$6.98K	Sell	1,425 -252	-15%	-$1.51K	﹤0.01%	3597
2016 Q3	$13K	Buy	1,677 +555	+49%	+$3.74K	﹤0.01%	3101
2016 Q2	$6.28K	Buy	+1,122	New	+$7.17K	﹤0.01%	3150
2016 Q1	–	Sell	-2,752	Closed	-$24K	–	3189
2015 Q4	$24K	Sell	2,752 -3,112	-53%	-$26.2K	﹤0.01%	2791
2015 Q3	$49.2K	Buy	5,864 +3,504	+148%	+$55.8K	﹤0.01%	2877
2015 Q2	$41.6K	Buy	+2,360	New	+$30.3K	﹤0.01%	2602

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

BNP Paribas Financial Markets's SRNE Position: Q1 2023 in Review

BNP Paribas Financial Markets sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 812,820 shares — an estimated $720K sold.

BNP Paribas Financial Markets first reported a position in SRNE in Q2 2015 and held it in 25 quarters. The position peaked at $1.71M in Q2 2020. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

BNP Paribas Financial Markets reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
BNP Paribas Financial Markets sold 812,820 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $720K.
BNP Paribas Financial Markets first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 25 quarters.
BNP Paribas Financial Markets's Sorrento Therapeutics, Inc. position peaked at $1.71M in Q2 2020.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2023, filed 12 May 2023.